Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > On GLP-1 agonists US Senate passes anti-patent thicket bill

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 02, 2024 2:19pm

85 Views

Post# 36205310

RE:RE:RE:RE:RE:RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

As lawyers at Sullivan IP Solutions see it, Pfizer shouldn’t have gone to the federal court, because “an arbitrator’s award is rarely overturned,” especially as the arbitrator was a retired federal court judge who has tried numerous pharmaceutical cases.

Seagen [and by implication Pfizer's due diligence] should have been more vigilant in monitoring its collaborator’s activities in the first place, the Sullivan lawyers said.

https://www.fiercepharma.com/pharma/without-pfizer-appeal-daiichi-sankyo-has-last-laugh-adc-patent-dispute-arbitration

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario